John Paul Lorbiecki
Known title: Chief Financial OfficerCIK: 0001900821
John Paul Lorbiecki's purchase track record
John Paul Lorbiecki has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/29/2022 | ACON | $10K | +25.4% | +25.4% | +14.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACON | ▲ Buy | Open Market | 4,100 | $2K | 12/29/2022 | View on chart |
| ACON | ▲ Buy | Open Market | 18,304 | $8K | 12/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
ACON Adds NYU Langone Health to CLARITY Trial Network
Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.
ACON Adds NYU Langone Health to CLARITY Trial Network. Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.